Prescription opioid pain relievers are essential to improving the quality of life for millions of Americans living with acute or chronic pain. Unfortunately, misuse, abuse, diversion, addiction and overdose of these drugs has created a serious public health epidemic in the United States. Since 2000, the rate of drug overdose deaths has increased 137%, with nearly half a million people dying from drug overdoses (52,404 deaths reported in 2015). Opioids, primarily prescription pain relievers and heroin, are the primary drugs associated with these deaths. In 2015, 63.1% of the drug overdose deaths involved an opioid.

This public health crisis touches ALL regions of the country, socioeconomic groups, and ethnicities. The federal government and the Food & Drug Administration (FDA) have intensified efforts to ensure safer prescribing of opioids. CO*RE provides continuing education to healthcare professionals for safe opioid prescribing in alignment with the FDA’s mission, following the FDA Blueprint (September, 2018).   

Citation:  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm?s_cid=mm6450a3_w and http://www.cdc.gov/drugoverdose/epidemic/index.html


Since 2012 CO*RE has delivered in-person and online ER/LA Opioid REMS education, to more than 215,000 clinicians via more than 500 CE/CME activities (through June 2016).

Our CO*RE collaborative uses Planned Change Assessment (PCA)® as a way to measure intended and completed changes in clinical practice following an educational experience. Through the PCA process, we gather information immediately following the event via questionnaire, 4-8 weeks after the event via survey, and up to six months after the event via follow-up interviews. Here is a sampling of data from CO*RE activity participants:


This graph shows the completed changes reported from our participants. 92% of those surveyed indicate they had completed specific changes in practice.


Although the CO*RE content is intended for ER/LA opioid prescribers, there are many professionals on the healthcare team who impact patient care and influence opioid therapy. This graph shows a range of important roles among prescribers and non-prescribers.


Here’s what people have to say about their experience:

“I like the videos of other healthcare providers having the difficult conversation with a patient – good modeling!”

– Physician

“I was so encouraged by what I heard that I intend to overcome my own discouragement and make time to work this into my treatment of pain patients. I will re-evaluate my decision to stop treating chronic pain.”

– New Mexico Clinician

“One of the best activities of this sort I’ve seen.”

– Physician

“The best CE I have completed so far. Thank you. Very clear but also very thorough – which is a tough balance to achieve. Thanks!”

– Nurse Practitioner


This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please click here for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.